Stem cell transplantation (SCT) remains the only proven curative therapy for chronic myelogenous leukemia (CML), but its use as a first-line therapeutic option has declined radically with the advent of Bcr-Abl targeted tyrosine kinase inhibitors (TKIs). Imatinib, the first TKI approved for use in patients with CML, offers significant disease control and impressive 5-year survival rates with minimal toxicity. As a result, imatinib has changed the way the majority of oncologists manage their patients with CML.
In 2006, dasatinib—a new, more potent TKI developed in response to imatinib resistance—was approved by the US Food and Drug Administration. Dasatinib is a dual Src-Abl TKI that has proven effective in imatinib-resistant patients with all phases of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia. A second compound still in development is nilotinib, which inhibits Bcr-Abl along with PDGFR and KIT, and has also demonstrated efficacy against most imatinib-resistant mutations. As a result of the significant efficacy and minimal toxicity seen with TKIs, treatment algorithms for CML today have shifted focus away from SCT and necessitate physicians to critically assess oral TKI-based therapies versus classical transplant options.
In an effort to better understand the future role of SCT in patients with CML in an era that is dominated by TKI-based therapeutic approaches, factors such as optimal patient selection and sequence strategies have become subject to continual debate and scrutiny amongst physicians. This activity is designed to bring blood and marrow transplantation specialists, hematologist/oncologists, hematologists, and medical oncologists up to speed with current treatment strategies for patients with CML, and evaluate the future role of SCT in select patient populations with this chronic disease.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologist/oncologists, hematologists, and other blood and marrow transplantation specialists involved in the management of patients with chronic myelogenous leukemia.
Learning Objectives
At the conclusion of this educational activity, participants should be better able to
•Identify prognostic features of patients with CML who may be optimal candidates for SCT
•Compare and contrast long-term survival outcomes associated with SCT- versus TKI-based therapy for management of patients with CML
•Discuss the roles that both SCT and newer, more potent TKIs play in the context of contemporary challenges for managing patients with CML, such as imatinib resistance
Accreditation/Designation of Credit Statement
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
If you previously completed and received credit for the live symposium on February 8, 2007, in Keystone, Colorado or the CD-ROM-based program entitled Tyrosine Kinase Inhibitors and Stem Cell Transplantation – Shaping The Treatment Landscape Of CML, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will the Medical College of Wisconsin award, duplicate credit for the activity. While learning benefits may be accrued by revisiting learning materials presented in Internet-based, self-directed activities, ultimately participants are still satisfying the activity's learning objectives for which they were originally awarded credit.
Chairperson
Sergio A. Giralt, MD
Associate Professor of Medicine
Clinical Medical Director
Department of Blood
and Marrow Transplantation
University of Texas
M.D. Anderson Cancer Center
Houston, Texas
Faculty
Jerald P. Radich, MD
Professor of Medicine
University of Washington
School of Medicine
Member, Clinical Research Division
Fred Hutchinson
Cancer Research Center
Seattle, Washington
Neil P. Shah, MD, PhD
Assistant Professor
of Hematology/Oncology
Department of Medicine
University of California, San Francisco
School of Medicine
San Francisco, California
Faculty Disclosure Summary
The Medical College of Wisconsin requires anyone in a position to control educational content of a CME activity to disclose his/her relevant financial relationships with industry. The planners and presenters of this activity have disclosed:
RSS / Subscribe